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COMPARISON OF DRUG TYPES IN INCIDENT REPORTS AMONG 
TEACHING HOSPITALS IN JAPAN
Hirose M1, Egami K1, Ohama K1, Tsuda Y1, Honda J1, Shima H1, Takemura T2, Okamoto 
K2, Yoshihara H2, Oh EH3
1Saint Mary’s Hospital, Kurume, Japan, 2Kyoto University Hospital, Kyoto, Japan, 3Hyupsung 
University, Hwaseong-Si, Gyeonggi-Do, South Korea
OBJECTIVES: Although incident reporting is very useful for securing patient safety, 
there are no previous studies comparing incident reports by extracting Drug Names 
from them. METHODS: We used 5,647 consecutive incident reports from Saint 
Mary’s Hospital (SMH) and 2,816 reports from Shimane University Hospital (SUH) 
between April ‘06 and March ‘08, and 3,087 reports from Kyoto University Hospital 
(KUH) between March ‘04 and August ‘05. RESULTS: 1) The number of top ﬁve 
ranking reports at SMH are 279 (Central Nervous System drugs, 4.9%(279/5647)), 
231 (Anti-diabetic drugs, 4.1%), 222 (Cardiovascular drugs, 3.9%), 127 (Anti-infec-
tive drugs, 2.2%) and 125 (Gastrointestinal drugs, 2.2%), in order. The numbers of 
those at KUH are 163 (CNS drugs, 5.3%), 130 (Cardiovascular drugs, 4.2%), 106 
(Gastrointestinal and Anti-infective drugs,each 3.4%), and 89 (Anti-diabetic drugs, 
2.9%). and the number of those at SUH are 244 (CNS drugs, 8.7%), 156 (Anti-dia-
betic drugs, 5.5%), 116 (Drugs affecting coagulation, 4.1%), 86 (Cardiovascular 
drugs, 3.1%), and 75 (Opiates, 2.7%). 2) CNS, Cardiovascular drugs are includued 
in the top ﬁve ranking drugs at all three hospitals. Gastrointestinal and Anti-infective 
drugs are included at SMH and KUH in top ﬁve. 3) CNS drugs featured much more 
at SMH and KUH, resulting from the higher proportion of the elderly inpatients at 
SUH in rural than those at SMH or KUH in urban. 4) The numbers with Cardiovas-
cular and Anti-diabetic drugs at all hospitals are huge, because Japanese patients are 
affected with cardiovascular disease and diabetes as adult lifestyle diseases. CONCLU-
SIONS: Different characteristics of the study areas might lead to these results. Further 
study should be conducted related with this topic. Furthermore, it would be very 
important for junior residents and new nursing stuff to be taught with emphasis on 
the careful attention with the above drugs through residency and education programs 
have a higher tendency to be involved with errors.
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CONSUMERS’ KNOWLEDGE OF GENERIC OTCS: A PHARMACIST 
INTERVENTION STUDY
Exaus CJ, Sangasubana N, Borja-Hart N, Alvarez G, Selagea AR, Rodriguez J, Rabionet S, 
Calderon JL
Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA
OBJECTIVES: To test the efﬁcacy of pharmacist interventions to increase consumers’ 
knowledge of generic Over-the-Counter (OTC) products. METHODS: A randomized-
controlled post-test only design was used in a judgment sample of adults recruited 
from a university-afﬁliated pharmacy excluding employees and students. Subjects were 
randomized into: 1) an intervention group receiving a pharmacist-developed pamphlet 
utilizing FDA information about generic drugs; 2) an intervention group receiving a 
5-minute pharmacist consultation about generic drugs with pamphlet reinforcement; 
and 3) a control group receiving neither intervention. Subjects completed a post-
intervention 7-item True/False questionnaire testing their knowledge on product dif-
ferences (2 items: price; physical appearance) and similarities (5 items: active 
ingredients; dosage form; safety; performance; quality) between generic and branded 
OTCs. A composite objective knowledge score (0–100) was calculated [(number of 
subjects’ correct responses/7)x100]. Student’s t-test, chi-square and analysis of vari-
ance (p < 0.05) were conducted to test the effects of the pharmacist interventions on 
consumers’ knowledge. RESULTS: A sample of 157 subjects completed the study 
(pamphlet = 53; pharmacist consultation = 51; control = 53). Nearly 71% were female 
with the average age being 47.6 (S.D. = 17.7) years. The majority (45.2%) had some 
college education, 24.5% high school or less, and 29.3% completing college. There 
were no signiﬁcant group differences in subjects’ sociodemographic characteristics. 
The average objective knowledge score was 84.4 (S.D. = 23.8), i.e., pamphlet = 90.9; 
pharmacist = 92.2; control = 67.7. Subjects in both intervention groups scored signiﬁ-
cantly higher than in the control group. However, the knowledge score difference 
between those receiving pamphlet only and pharmacist consultation with pamphlet 
was not signiﬁcant. CONCLUSIONS: The study’s educational interventions, whether 
in the form of a written pamphlet or a combination of a verbal pharmacist consulta-
tion with pamphlet reinforcement, signiﬁcantly increased consumers’ knowledge of 
generic OTCs. These ﬁndings indicate the importance of pharmacist involvement and 
participation in both the design and implementation of written and verbal patient 
education of generic OTCs.
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CMS VS. NICE COVERAGE OF TECHNOLOGIES: HOW DO THEY 
COMPARE?
Kamae MS, Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: The US Centers for Medicare and Medicaid Services (CMS) and the 
UK’s National Institute for Health and Clinical Excellence (NICE) issue coverage 
decisions or guidances about medical technology. We compared the overlap in the 
technologies considered and the decisions/recommendations between the two agencies. 
METHODS: We reviewed all NCDs (n = 138) posted on the CMS website between 
1999 through 2009 and all guidances (n = 613) posted on NICE’s website since 1999. 
We included all types of NICE guidances, including cancer service guidances, clinical 
guidelines, interventional procedures, public health guidances, and technology 
appraisals. We compared CMS and NICE documents to determine overlap in the 
technologies considered and the consistency of the recommendations. RESULTS: Of 
138 CMS NCDs, 58 pertained to technologies also evaluated by NICE. Medical 
procedures (n = 14) and medical devices (n = 12) were the most common overlapping 
technologies. Pharmaceuticals (n = 3) least frequently overlapped, in large part because 
Medicare rarely uses NCD for drugs. In terms of recommendations for overlapping 
technologies, 79% of NCDs and 93% of NICE guidances were favorable. 86% of 
overlapping technologies had the same direction of the recommendation, though there 
were some differences in the target population and other details. In the 8 “discrepant” 
decisions (where CMS and NICE recommendations disagreed), most often CMS issued 
a non-coverage decision while NICE supported the technology or allowed clinicians 
to use the technology with special arrangements. These include technologies such as 
screening computed tomography colonography for colorectal cancer and lumbar arti-
ﬁcial disc replacement for the patients over sixty years of age. CONCLUSIONS: Less 
than half of the technologies that Medicare considered in NCDs were also evaluated 
in NICE guidances. Where the two agencies evaluated the same technologies, recom-
mendations were mostly consistent. However, where there were disagreements, CMS 
tended to be more restrictive than NICE.
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ARE GOVERNMENT BASED REIMBURSEMENT PROGRAMS PERCEIVED 
BETTER OR WORSE COMPARED TO COMMERCIAL MANAGED CARE 
INSURANCE PAYERS BY PHARMACISTS?
Patel J, Goyal RK, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: Reimbursement issues in Medicare Part D and Medicaid plans have 
been argued to cause ﬁnancial instability in pharmacies. Is reimbursement amount and 
processing time different in the three major health insurance providers, namely Medi-
care part D, Medicaid and commercial managed care insurance payers? METHODS: 
A cross-sectional survey of pharmacists processing claims in independent pharmacies 
in the Houston metropolitan area was conducted using a 5-point Likert-scale question-
naire. Reimbursement rate was deﬁned as the actual percentage of claimed amount 
received from insurance payers. Reimbursement processing time was deﬁned as the 
number of days taken to receive reimbursement after claim adjudication. The question-
naire addressed issues with respect to adequacy and improvement of reimbursement 
rates and processing times across three insurance payers. Further satisfaction and 
whether pharmacists encountered cash-ﬂow problems due to reimbursement issues 
was obtained. Descriptive analyses were conducted and the analysis of variance was 
performed, followed by Tukey’s multiple comparison method to identify differences 
between payment sources. RESULTS: Pharmacists, in general, disagreed that the 
reimbursement rate and processing time were adequate in any of the three categorized 
payment processors. They perceived that the mean (SD) reimbursement rate from 
commercial managed care plans (2.05 (0.87), p < 0.001) was not adequate compared 
to Medicare Part D (2.6 (0.9)), and Medicaid plans (2.75 (0.95)). Pharmacists’ per-
ceived processing time was better in Medicaid plans (3.05 (1.04), p < 0.001) as 
compared to Medicare Part D (2.5 (0.98)), and commercial managed care plans (2.64 
(0.87)). They were dissatisﬁed with the process of reimbursement which had created 
cash ﬂow problems for their pharmacy and this perception was consistent across all 
payers. CONCLUSIONS: The reimbursement rate and the processing time for pre-
scription drug claims were believed to be inadequate in all three payment processors. 
Government programs were perceived to be better as compared to commercial 
managed care insurance programs.
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LISTING AND REIMBURSEMENT OF NEW DRUGS IN NATIONAL 
HEALTH INSURANCE—AN EMPIRICAL EXPERIENVCE OF TAIWAN
Huang WF1, Hsieh CF1, Chen GT2
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OBJECTIVES: We aim to present the empirical experience of new drug listing and 
reimbursement under Taiwan’s National Health Insurance (NHI), and to analyze the 
performance of such mechanism. We also attempt to assess its impact to the research-
based pharmaceutical company and the public access to pharmaceutical innovations. 
METHODS: The materials are based on the documentation of Taiwan’s NHI Drug 
Review Committee (DRC) over 11 years period (1996∼2006). We deﬁned the criteria 
of pricing methods into 9 categories: International Price Comparison, Comparison 
with Similar Products with Equivalent Therapeutic Effects, Price Proportion Method, 
Price Addition, Orphan Drugs, The Lowest Available International Price, Cost Analy-
sis, Grouping and Others. RESULTS: The total number of new drugs that applied for 
NHI listing and reimbursement during 1996∼2006 was 787, and the number of peti-
tion cases was 325(41%). The total number of new drugs with ﬁnal pricing decisions 
in this study was 566. Among them, 298 items were issued with reimbursement price 
without petition, and the remaining 268 new drugs received their reimbursement 
prices after petition on initial pricing decisions. The approved price was averaged 74% 
of the international median prices, and was only 65% of international median prices 
among petition cases. The top three methods of pricing are Price Proportion Method 
(37.1%), Equivalent Therapeutic Effect with Similar Product (23.5%), and Interna-
tional Price Comparison (14.7%). Although NHI continues to facing ﬁnancial crisis 
in the past 10 years, the price of reimbursement remained approximately 71% of their 
respective application prices during all the period. CONCLUSIONS: The policy direc-
tion of NHI pricing and reimbursement is to ensure that resources serve the highest 
priorities of the population’s health needs in an efﬁcient way. It is worthwhile to 
